Reports
Sale
Global Lung Cancer Screening Market Size, Analysis, Report: By Type: Low Dose Computed Tomography (LDCT), X-ray; By Age group: 50 and Older, Below 50; By End User: Hospitals, Diagnostic Centers, Others; Regional Analysis; Market Dynamics: SWOT Analysis, Porter’s Five Forces Model, Key Demand Indicators; Supplier Landscape; 2024-2032
Global Lung Cancer Screening Market Outlook
The global lung cancer screening market size was valued at USD 2.5 billion in 2023, driven by the increasing number of cases related to lung cancer across the globe. The market size is anticipated to grow at a CAGR of 8.2% during the forecast period of 2024-2032 to achieve a value of USD 5.1 billion by 2032.
Lung Cancer Screening: Introduction
Screening is the process of examining cancer in individuals with no symptoms. This can help detect cancer at an early stage, which can increase the chances of successful treatment. Scientists conduct research on screening tests to identify those that have the least harmful effects and the most benefits. Cancer screening trials are also conducted to determine whether early detection (finding cancer before it causes symptoms) can help a person live longer or reduce the risk of dying from the disease. For certain types of cancer, the chances of recovery are higher if the disease is detected and treated at an early stage.
Global Lung Cancer Screening Market Analysis
The lung cancer screening market growth is driven by key trends such as technological advancements, updated screening guidelines, robust research activities, and ongoing clinical trials. The integration of Artificial Intelligence (AI) and Machine Learning (ML) in lung cancer screening represents a pivotal take. AI/ML tools have the capability to assess chronic diseases on CT scans, offering opportunities for enhanced, high-quality screening and enhancing population health.
Furthermore, the updated screening guidelines released by the American Cancer Society (ACS) on November 1, 2023, are expected to play a pivotal role in saving more lives. The revised guidelines recommend annual lung cancer screening for individuals aged 50 to 80 with a history of smoking, aligning closely with the 2021 U.S. Preventive Services Task Force (USPSTF) recommendations but eliminating the 'years since quitting' requirement. These guidelines provide a comprehensive framework for healthcare providers, fostering a more targeted and efficient screening process.
Research activities, particularly in the realm of Low dose computed tomography (LDCT) screening, reinforce the effectiveness of lung cancer screening in reducing mortality. Recent studies showcased at the International Association for the Study of Lung Cancer emphasize the significance of LDCT in early detection.
Moreover, innovative Artificial Intelligence models developed by MIT researchers, offering personalized risk assessment based on CT scans, add another layer of sophistication to lung cancer screening, bolstering the global lung cancer screening market demand.
The market is further driven by ongoing clinical trials, exemplified by the NYU Langone Health-sponsored trial focusing on lung cancer biomarkers and screening. This extensive study, initiated in 2000 and set to conclude in 2023, aims to identify and validate biomarkers for early lung cancer detection, particularly in high-risk individuals. The trial underscores the importance of a personalized approach in screening, emphasizing the potential to detect preneoplastic cellular changes and lesions in at-risk populations.
Global Lung Cancer Screening Market Segmentations
Market Breakup by Type
- Low dose computed tomography (LDCT)
- X-ray
Market Breakup by Age Group
- 50 and older
- Below 50
Market Breakup by End User
- Hospitals
- Diagnostic Centers
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Lung Cancer Screening Market Overview
The market is expected to be propelled by several key factors highlighting the urgency and importance of early detection. The increasing utilization of low dose computed tomography (LDCT) for lung cancer screening by healthcare professionals is a major factor driving market growth. The endorsement of annual screening for asymptomatic individuals aged 50 to 80 years, with a history of smoking (current or former) and a ≥20 pack-year smoking history, by esteemed organizations such as the American Cancer Society has led to a surge in screening procedures. This strong recommendation, supported by moderate-quality evidence, signifies the important role of LDCT in identifying lung cancer at its early, more treatable stages. The rise in awareness regarding innovative and affordable lung cancer screening techniques, particularly in developing countries is among the major factors propelling the global lung cancer screening market growth.
Lung cancer accounts for the highest mortality rates among both men and women globally which is a great concern. Smoking accounts for approximately 85% of all lung cancer cases, highlighting the importance of early screening for patients at risk. With an estimated 238,340 new cases expected in the United States in 2023, lung cancer ranks as the second most common cancer in the country. This prevalence exhibits the necessity for expanded and efficient screening initiatives. The projected increase in screening procedures, driven by the imperative for early detection, is poised to create a substantial demand for lung cancer screening technologies and services, thereby boosting the growth of the global lung cancer screening market.
Global Lung Cancer Screening Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Canon Medical Systems
- Eon Health
- Fujifilm Holdings Corporation
- Koninklijke Philips N.V.
- Medtronic Plc
- Microsoft Corporation (Nuance Communications, Inc)
- Penrad Technologies Inc.
- Miltenyi Biotec
- Volpara Solutions Limited.
- General Electric
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Age group |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Lung Cancer Screening Market Overview
3.1 Global Lung Cancer Screening Market Historical Value (2017-2023)
3.2 Global Lung Cancer Screening Market Forecast Value (2024-2032)
4 Global Lung Cancer Screening Market Landscape
4.1 Global Lung Cancer Screening: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Lung Cancer Screening: Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Technology
4.2.3 Analysis by Applications
5 Global Lung Cancer Screening Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Lung Cancer Screening Market Segmentation
6.1 Global Lung Cancer Screening Market by Type
6.1.1 Market Overview
6.1.2 Low Dose Computed Tomography (LDCT)
6.1.3 X-ray
6.2 Global Lung Cancer Screening Market by Age group
6.2.1 Market Overview
6.2.2 50 and older
6.2.3 Below 50
6.3 Global Lung Cancer Screening Market by End User
6.3.1 Market Overview
6.3.2 Hospitals
6.3.3 Diagnostic Centers
6.3.4 Others
6.4 Global Lung Cancer Screening Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Lung Cancer Screening Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Lung Cancer Screening Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Lung Cancer Screening Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Lung Cancer Screening Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Lung Cancer Screening Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Canon Medical Systems
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Eon Health
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Fujifilm Holdings Corporation
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Koninklijke Philips N.V.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Medtronic Plc
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Microsoft Corporation (Nuance Communications, Inc)
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Penrad Technologies Inc.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 `Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Miltenyi Biotec
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Volpara Solutions Limited.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 General Electric
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
18 Key Opinion Leaders (KOL) Insights (Additional Insight)
19 Company Competitiveness Analysis (Additional Insight)
19.1 Very Small Companies
19.2 Small Companies
19.3 Mid-Sized Companies
19.4 Large Companies
19.5 Very Large Companies
20 Payment Methods (Additional Insight)
20.1 Government Funded
20.2 Private Insurance
20.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 2.5 billion in 2023, driven by the increased government initiatives.
The market is anticipated to grow at a CAGR of 8.2% during the forecast period of 2024-2032 and is likely to reach a market value of USD 5.1 billion by 2032.
The developing healthcare infrastructure, rising disposable incomes, and the increasing usage of low dose computed tomography (LDCT) for lung cancer screening is a major factor driving the market growth.
The integration of Artificial Intelligence (AI) and Machine Learning (ML) in lung cancer screening is a major trend influencing the market growth.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is currently leading the global market.
Different types of lung cancer screenings include Low dose computed tomography (LDCT) and X-ray.
Different age groups include 50 and older and below 50.
The end users in the market include hospitals and diagnostic centers, among others.
Key players involved in the market are Canon Medical Systems, Eon Health, Fujifilm Holdings Corporation, Koninklijke Philips N.V., Medtronic Plc, Microsoft Corporation (Nuance Communications, Inc), Penrad Technologies Inc., Miltenyi Biotec, Volpara Solutions Limited., and General Electric.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER